Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 17.18
OXBT's Cash to Debt is ranked higher than
71% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. OXBT: 17.18 )
OXBT' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 17.18

Equity to Asset 0.89
OXBT's Equity to Asset is ranked higher than
91% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OXBT: 0.89 )
OXBT' s 10-Year Equity to Asset Range
Min: -1.28   Max: 0.94
Current: 0.89

-1.28
0.94
F-Score: 3
Z-Score: 8.28
M-Score: -0.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -420.50
OXBT's Operating margin (%) is ranked higher than
58% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. OXBT: -420.50 )
OXBT' s 10-Year Operating margin (%) Range
Min: -21704.26   Max: -420.5
Current: -420.5

-21704.26
-420.5
Net-margin (%) -763.05
OXBT's Net-margin (%) is ranked higher than
55% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. OXBT: -763.05 )
OXBT' s 10-Year Net-margin (%) Range
Min: -22355.32   Max: -763.05
Current: -763.05

-22355.32
-763.05
ROA (%) -296.01
OXBT's ROA (%) is ranked lower than
53% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. OXBT: -296.01 )
OXBT' s 10-Year ROA (%) Range
Min: -873.49   Max: -14.69
Current: -296.01

-873.49
-14.69
ROC (Joel Greenblatt) (%) -2531.22
OXBT's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. OXBT: -2531.22 )
OXBT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4095.71   Max: -163.32
Current: -2531.22

-4095.71
-163.32
Revenue Growth (%) 141.00
OXBT's Revenue Growth (%) is ranked higher than
99% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. OXBT: 141.00 )
OXBT' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 141
Current: 141

0
141
EBITDA Growth (%) -34.90
OXBT's EBITDA Growth (%) is ranked higher than
57% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. OXBT: -34.90 )
OXBT' s 10-Year EBITDA Growth (%) Range
Min: -34.9   Max: 43.4
Current: -34.9

-34.9
43.4
EPS Growth (%) -16.50
OXBT's EPS Growth (%) is ranked higher than
71% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. OXBT: -16.50 )
OXBT' s 10-Year EPS Growth (%) Range
Min: -40.5   Max: 83.6
Current: -16.5

-40.5
83.6
» OXBT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OXBT



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.33
OXBT's P/B is ranked higher than
80% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. OXBT: 2.33 )
OXBT' s 10-Year P/B Range
Min: 3.07   Max: 51.06
Current: 2.33

3.07
51.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.90
OXBT's Price/Net Cash is ranked lower than
73% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. OXBT: 25.90 )
OXBT' s 10-Year Price/Net Cash Range
Min: 4.42   Max: 7650.75
Current: 25.9

4.42
7650.75
Price/Net Current Asset Value 24.67
OXBT's Price/Net Current Asset Value is ranked lower than
72% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. OXBT: 24.67 )
OXBT' s 10-Year Price/Net Current Asset Value Range
Min: 4.39   Max: 7650.75
Current: 24.67

4.39
7650.75
Price/Tangible Book 17.86
OXBT's Price/Tangible Book is ranked lower than
77% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. OXBT: 17.86 )
OXBT' s 10-Year Price/Tangible Book Range
Min: 3.83   Max: 800.08
Current: 17.86

3.83
800.08
Forward Rate of Return (Yacktman) -131.80
OXBT's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. OXBT: -131.80 )
OXBT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2   Max: 22.6
Current: -131.8

2
22.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:YBOP.Germany
Oxygen Biotherapeutics, Inc. was originally formed as a New Jersey corporation in 1967 under the name Rudmer, David & Associates, Inc., and subsequently changed its name to Synthetic Blood International, Inc. The Company is engaged in the business of developing biotechnology products with a focus on oxygen delivery to specific target tissues. It is currently developing Oxycyte, a systemic perfluorocarbon, or PFC, product as oxygen carrier for use in situations of acute ischemia. In addition, it has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. The Company is actively pursuing agreements with multiple manufacturers to ensure that it is able to consistently obtain its raw materials and topical products timely, within its defined specifications, and at competitive prices. The manufacture and distribution of Oxycyte, as well as its other products, and the operation of its manufacturing facilities will require the approval of United States government authorities as well as those of foreign countries.
» More Articles for OXBT

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide